



## PRESS RELEASE

### GENFIT to Host R&D Event on March 31, 2016

**Lille (France), Cambridge (Massachusetts, United States), March 29, 2016** – GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that the company will host an R&D Event on Thursday, March 31 in New York City from 8:00am – 10:00am ET, with a live webcast.

GENFIT will discuss:

- › Progress with GENFIT’s lead development compound, Elafibranor, currently in Phase 3 for treating NASH (nonalcoholic steatohepatitis),
- › GENFIT’s program in non-invasive biomarker diagnostic solutions for NASH, and
- › Future development plans targeting additional hepatic and gastrointestinal diseases.

Presentations will also include a key opinion leader in hepatology, **Professor Manal Abdelmalek, M.D., MPH, Associate Professor of Medicine, Division of Gastroenterology & Hepatology Duke University, VA, USA** to discuss perspectives on the treatment of NASH and other associated diseases.

The event will be webcast live and can be accessed via link at [www.genfit.com](http://www.genfit.com). For those not able to listen to the live broadcast, a replay will be archived for 7 days and available on [www.genfit.com](http://www.genfit.com).

#### **About Elafibranor:**

Elafibranor (GFT505) is GENFIT’s lead pipeline product. Elafibranor is an oral once-daily treatment, and a first-in-class drug acting via dual peroxisome proliferator-activated alpha/delta pathways to treat nonalcoholic steatohepatitis (NASH). Elafibranor is believed to address multiple facets of NASH, including inflammation, insulin sensitivity, lipid/metabolic profile, and liver markers.

#### **About NASH:**

“NASH”, or nonalcoholic steatohepatitis, is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. The disease is



## PRESS RELEASE

associated with long term risk of progression to cirrhosis, a state where liver function is diminished, leading to liver insufficiency, and also progression to liver cancer.

### About GENFIT:

GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH – Nonalcoholic steatohepatitis) and more generally the gastrointestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, Elafibranor (GFT505), completed a Phase 2b study in NASH and is currently in a Phase 3 study. With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### Forward-Looking Statement Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, results of clinical data from the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding Elafibranor and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4.2 "Risk Factors" ("Facteurs de Risque") of the Company's Annual Financial Report for the year ended December 31, 2015, which is available on GENFIT's website ([www.genfit.com](http://www.genfit.com)). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

### CONTACT

**GENFIT** | Jean-François Mouney – Chairman & CEO | Ph. +333 2016 4000

**MILESTONES – Press Relations** | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)

**GENFIT** | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | [www.genfit.com](http://www.genfit.com)